NASDAQ:AMGN - Amgen Stock Price, Forecast & News

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Amgen declared a quarterly dividend on Wednesday, December 11th. Investors of record on Friday, February 14th will be given a dividend of $1.60 per share on Friday, March 6th. This represents a $6.40 annualized dividend and a yield of 2.65%. The ex-dividend date of this dividend is Thursday, February 13th. This is a positive change from Amgen's previous quarterly dividend of $1.45. View Amgen's Dividend History.

Amgen declared that its Board of Directors has authorized a share buyback plan on Friday, February 2nd 2018, which allows the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company's management believes its stock is undervalued.

Amgen, Inc. (NASDAQ:AMGN) announced its quarterly earnings results on Tuesday, October, 29th. The medical research company reported $3.66 earnings per share for the quarter, topping analysts' consensus estimates of $3.53 by $0.13. The medical research company had revenue of $5.74 billion for the quarter, compared to analysts' expectations of $5.63 billion. Amgen had a return on equity of 80.26% and a net margin of 34.48%. The business's quarterly revenue was down 2.8% on a year-over-year basis. During the same period in the previous year, the business earned $3.69 earnings per share. View Amgen's Earnings History.

Amgen is scheduled to release their next quarterly earnings announcement on Thursday, January 30th 2020. View Earnings Estimates for Amgen.

Amgen will be holding an earnings conference call on Thursday, January 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Amgen issued an update on its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided earnings per share (EPS) guidance of $$14.50-14.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $$14.44. The company issued revenue guidance of $$23.1-23.3 billion, compared to the consensus revenue estimate of $$23.01 billion.

21 brokers have issued 12-month price targets for Amgen's stock. Their forecasts range from $198.00 to $277.00. On average, they anticipate Amgen's share price to reach $236.29 in the next year. This suggests that the stock has a possible downside of 2.2%. View Analyst Price Targets for Amgen.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 9 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amgen.

Media coverage about AMGN stock has trended positive on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Amgen earned a daily sentiment score of 3.0 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the next several days. View News Stories for Amgen.

Amgen saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 9,910,000 shares, an increase of 8.2% from the December 15th total of 9,160,000 shares. Based on an average trading volume of 2,130,000 shares, the days-to-cover ratio is currently 4.7 days. Currently, 1.7% of the company's stock are short sold. View Amgen's Current Options Chain.

Some companies that are related to Amgen include Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), Alibaba Group (BABA), NVIDIA (NVDA), Walt Disney (DIS), Cisco Systems (CSCO), Intel (INTC), AT&T (T), Home Depot (HD), JPMorgan Chase & Co. (JPM) and Gilead Sciences (GILD).

Amgen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Johanson Financial Advisors Inc. (0.20%), PGGM Investments (0.09%), Douglass Winthrop Advisors LLC (0.05%), Nisa Investment Advisors LLC (0.05%), Gateway Investment Advisers LLC (0.05%) and Manning & Napier Group LLC (0.03%). Company insiders that own Amgen stock include Cynthia M Patton, David W Meline, Jonathan P Graham, R Sanders Williams, Ronald D Sugar, Sean E Harper and Tyler Jacks. View Institutional Ownership Trends for Amgen.

AMGN stock was sold by a variety of institutional investors in the last quarter, including PGGM Investments, Commerzbank Aktiengesellschaft FI, Gateway Investment Advisers LLC, Tocqueville Asset Management L.P., Meag Munich Ergo Kapitalanlagegesellschaft MBH, Creative Financial Designs Inc. ADV, State of Alaska Department of Revenue and Nisa Investment Advisors LLC. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton, David W Meline, Jonathan P Graham, R Sanders Williams and Ronald D Sugar. View Insider Buying and Selling for Amgen.

AMGN stock was purchased by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., DNB Asset Management AS, Manning & Napier Group LLC, Fluent Financial LLC, Camelot Portfolios LLC, Sanders Morris Harris LLC, Private Trust Co. NA and Alpha Cubed Investments LLC. View Insider Buying and Selling for Amgen.

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AMGN stock can currently be purchased for approximately $241.49.

Amgen has a market capitalization of $143.49 billion and generates $23.75 billion in revenue each year. The medical research company earns $8.39 billion in net income (profit) each year or $14.40 on an earnings per share basis. Amgen employs 21,500 workers across the globe.View Additional Information About Amgen.

The official website for Amgen is http://www.amgen.com/.

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]